Polycythemia vera (PV), essential thrombocythemia (ET), and myeloid metaplasia with
myelofibrosis (MMM) are clonal disorders arising from hematopoietic progenitors. An internet-…

Background Data on patients with COVID-19 who have cancer are lacking. Here we characterise
the outcomes of a cohort of patients with cancer and COVID-19 and identify potential …

Background Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically
significant activity in myelofibrosis. Methods In this double-blind trial, we randomly assigned …

Therapeutic decision-making in primary myelofibrosis (PMF) is becoming more challenging
because of the increasing use of allogeneic stem cell transplantation and new …

Recently, a gain-of-function MPL mutation, MPLW515L, was described in patients with
JAK2V617F-negative myelofibrosis with myeloid metaplasia (MMM). To gain more information on …

Background Myelofibrosis is a Philadelphia chromosome–negative myeloproliferative neoplasm
associated with cytopenias, splenomegaly, poor quality of life, and shortened survival. …

BACKGROUND. Few objective data exist on the burden of fatigue and other constitutional
symptoms in patients with myeloproliferative disorders (MPD). METHODS. The authors used …

Purpose Myeloproliferative neoplasm (MPN) symptoms are troublesome to patients, and
alleviation of this burden represents a paramount treatment objective in the development of …

To provide basic information about occurrence and outcome of essential thrombocythemia (ET)
and agnogenic myeloid metaplasia (AMM), we used the Rochester Epidemiology Project …

Among 2333 consecutive patients with myelofibrosis with myeloid metaplasia (MMM) seen
at our institution, 91 fulfilled the World Health Organization (WHO) criteria for leukemic …